Correlation Between Eliem Therapeutics and Cue Biopharma

Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eliem Therapeutics and Cue Biopharma, you can compare the effects of market volatilities on Eliem Therapeutics and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Cue Biopharma.

Diversification Opportunities for Eliem Therapeutics and Cue Biopharma

-0.75

Correlation Coefficient

Eliem Therapeutics  Cue Biopharma

Pay attention - limited upside

The 3 months correlation between Eliem and Cue is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Cue Biopharma go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Cue Biopharma

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Cue Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Eliem Therapeutics is 2.47 times less risky than Cue Biopharma. The stock trades about -0.24 of its potential returns per unit of risk. The Cue Biopharma is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  66.00  in Cue Biopharma on August 31, 2024 and sell it today you would earn a total of  56.00  from holding Cue Biopharma or generate 84.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	98.41%
Values	Daily Returns

Eliem Therapeutics  vs.  Cue Biopharma

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Cue Biopharma

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eliem Therapeutics and Cue Biopharma

The main advantage of trading using opposite Eliem Therapeutics and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.

The idea behind Eliem Therapeutics and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.